Companies › Biohaven Therapeutics
7 active drug programs in 10 registered trials: 5 Phase 1, 4 Phase 2, 1 Phase 3; Neurology, Oncology, Metabolic and endocrine, Genitourinary; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BHV-1300 unclear - code-named drug | – | Phase 3 | Graves Disease | Sep 2027 |
| BHV-7000 ATP-sensitive potassium channel opener | Ion channels | Phase 2 | Focal Epilepsy; Familial Erythromelalgia | Dec 2026 |
| BHV-8000 | – | Phase 2 | Parkinson Disease | Aug 2027 |
| Taldefgrobep Alfa FGF21 receptor agonist (FGF21 analog) | FGFR1, FGFR4, KLB | Phase 2 | Obesity | – |
| BHV-1400 | – | Phase 1 | IgA Nephropathy | Jul 2027 |
| BHV-1510 | – | Phase 1 | Solid Tumor | Feb 2028 |
| BHV-1530 | – | Phase 1 | Solid Tumor | Mar 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07281495 | Taldefgrobep Alfa | Phase 2 | Obesity | Metabolic and endocrine | Sep 2026 |
| NCT06309966 | BHV-7000 | Phase 2 | Focal Epilepsy | Neurology | Oct 2026 |
| NCT06132893 | BHV-7000 | Phase 2 | Focal Epilepsy | Neurology | Dec 2026 |
| NCT07054684 | BHV-1400 | Phase 1 | IgA Nephropathy | Genitourinary | Jul 2027 |
| NCT06976268 | BHV-8000 | Phase 2 | Parkinson Disease | Neurology | Aug 2027 |
| NCT06980649 | BHV-1300 | Phase 1 | Graves Disease | Metabolic and endocrine | Sep 2027 |
| NCT07262268 | BHV-7000 | Phase 1 | Familial Erythromelalgia | Neurology | Nov 2027 |
| NCT07661056 | BHV-1300 | Phase 3 | Graves Disease | Metabolic and endocrine | Jan 2028 |
| NCT06384807 | BHV-1510 | Phase 1 | Solid Tumor | Oncology | Feb 2028 |
| NCT06874335 | BHV-1530 | Phase 1 | Solid Tumor | Oncology | Mar 2029 |
Cash and short-term investments of $161m on 2026-09-30; operating cash outflow about $459m a year; runway about 4 months at that burn, to Feb 2027; 1 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Tyra Biosciences Denali Therapeutics Hanmi Pharmaceutical Company Hangzhou Zhongmei Huadong Pharmaceutical Luye Pharma Group
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.